WESTMINSTER, CO (September 14, 2013) – Surefire Medical, Inc., the developer of a brand  new class of infusion systems designed to maximize direct-to-tumor drug delivery without  reflux, today announced that presentations at the Cardiovascular and Interventional Radiological  Society (CIRSE) meeting make the economic case for use of the new Surefire Infusion System  (SIS). Research presented today in Barcelona found that:

  • The SIS catheter group had a significant reduction in procedure time, fluoroscopy time, and contrast dose in pre-treatment angiograms
  • Without use of coils, no non-target embolization occurred in the SIS group during treatment
  • Using the SIS catheter to protect non-target organs costs significantly less than coil embolization in direct-to-tumor cancer treatment

“The Surefire Infusion System is a viable first-line alternative to traditional retrievable coil embolization for protecting non-target organs and may lead to decreased overall costs, procedure time, fluoroscopy time, and contrast exposure when treating cancer patients with radioembolization,” said principal investigator Steven Kikolski, MD of the University of California San Diego (UCSD).

Additional SIS-focused presentations at CIRSE
Five additional presentations and posters at CIRSE focusing on the Surefire Infusion System

  • Confirm the safety of performing chemoembolization and radioembolization procedures without coiling
  • Present a pilot study of a single procedure for mapping and radioembolization
  • Detail the new ability to measure blood pressure changes that can signal the endpoint of embolization
  • Discuss the feasibility of bariatric embolization to reduce obesity

“We are extremely gratified by the rapidly growing body of clinical evidence showing that both patients and medical institutions benefit by the use of the Surefire Infusion System for cancer treatment,” said Surefire President and CEO Jim Chomas. “The new technology advances the better tolerated, minimally-invasive embolization techniques. It reduces procedure time and cost, and makes treatment feasible for patients previously thought untreatable.”

About Surefire Medical
Surefire Medical, Inc., based in Westminster, Colo., was founded in 2009 to develop innovative infusion systems for the interventional radiology and interventional oncology markets. Surefire’s infusion systems are designed to precisely deliver embolic agents through a unique microcatheter with an expandable tip that collapses in forward flow and dynamically expands to the vessel wall in reverse flow in order to maximize targeted delivery, minimize reflux and reduce damage to healthy tissue. The Surefire Infusion System-ST, LT and specialty catheters have received regulatory approval in the U.S., Europe, and New Zealand. For more information, please visit www.surefire.local.

Achievement

Clinical Data Shows Surefire Technology Achieved 79% Objective Response versus 37% Using a Standard Microcatheter in Treating Primary Liver Cancer. Study presented at SIR 2017 Annual Scientific Meeting.